Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates (Q39484948)

12 September 2017

title

Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates (English)

1 reference

12 September 2017

0 references

Indresh K Srivastava

1

1 reference

12 September 2017

Elaine Kan

2

1 reference

12 September 2017

Yide Sun

3

1 reference

12 September 2017

Victoria A Sharma

4

1 reference

12 September 2017

Jimna Cisto

5

1 reference

12 September 2017

Brian Burke

6

1 reference

12 September 2017

Ying Lian

7

1 reference

12 September 2017

Susan Hilt

8

1 reference

12 September 2017

Zohar Biron

9

1 reference

12 September 2017

Karin Hartog

10

1 reference

12 September 2017

Leonidas Stamatatos

11

1 reference

12 September 2017

Ruben Diaz-Avalos

12

1 reference

12 September 2017

R Holland Cheng

13

1 reference

12 September 2017

Jeffrey B Ulmer

14

1 reference

12 September 2017

Susan W Barnett

15

1 reference

12 September 2017

language of work or name

English

0 references

publication date

3 December 2007

1 reference

12 September 2017

1 reference

12 September 2017

volume

372

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

273-290

1 reference

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Viral evolution and challenges in the development of HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Structure of an unliganded simian immunodeficiency virus gp120 core

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Progress in HIV vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Determination of molecular weight of membrane proteins by the use of low-angle laser light scattering combined with high-performance gel chromatography in the presence of a non-ionic surfactant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Defining the Protective Antibody Response for HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Energetics of the HIV gp120-CD4 binding reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Protein−Protein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.10.022

7 January 2021

10.1016/J.VIROL.2007.10.022

Identifiers

DOI

1 reference

release_kxpati6ijvbqdajkhzxympycme

12 September 2017

Fatcat ID

0 references

1 reference